

MRI whole brain volume: Percentage change from Week 24 by visit
ITT population

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Week 24 to Week 156			
n	155	175	
Mean	-1.164	-0.948	0.0070
SD	0.8228	0.7193	

(a)p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for
<=5.5 or >=6) and baseline normalized brain volume.

natalizumab subjects had a baseline after 6 months of treatment and the placebo-to-natalizumab group had
a baseline of initiation of treatment